Data layers Raw facts Calculated Model prediction AI interpretation

Company Overview

Stock NameBioheart-B
Stock Code02185
Company Full NameTo be extracted
IndustryHealthcare
Principal Activities中國領先的創新介入式心血管裝置公司,專注於全降解支架(BRS)及腎神經阻斷(RDN)兩種療法,以解決冠狀或外周動脈疾病及未控高血壓、頑固性高血壓的未滿足醫療需求。
Listing Date2021-12-23
Listing Rules EraOld Rules
Listing Rules ChapterTo be extracted
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)中國上海市浦東新區張江高科技產業東區瑞慶路590號4幢3層302室
Business Address (Hong Kong)香港銅鑼灣希慎道33號利園一期19樓1901室
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websitebio-heart.com
Share Registrar香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited)
Registrar Contact(852)2862 8628
A-Share/US Dual ListingNo

Offering Information

Offering Mechanism Mechanism A
Offer PriceHK$ 21.25 / shares
Offer Price RangeFinal offer price only, no range
Lot Size500 shares
Entry ThresholdHK$ 10,625
Par ValueRMB 1.0 / shares
Offer Period2021-12-13 to 2021-12-16
Global Offering Shares23,937,000 shares
HK Public Offer Shares (Initial)2,394,000 shares (10.0%)
Public Offer Lots (Initial)4,788lots (Pool A2,394lots,Pool B2,394lots)
International Placing Shares (Initial)21,543,000 shares (90.0%)
Offer Ratio~10.0%
Total Shares Post-IPO243,937,000 shares
Greenshoe (Over-allotment Option)Yes
Stabilizing Manager (Greenshoe)To be extracted
Cornerstone ShareNo cornerstone investors
Clawback TiersTo be extracted
Reallocation OptionYes
Total Global Offering SizeHK$ 508,661,250

Subscription Tiers

Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.

Pool A
Lots SubscribedShares SubscribedSubscription Amount (HKD)
1 lots 500 HK$ 10,625
2 lots 1,000 HK$ 21,250
3 lots 1,500 HK$ 31,875
4 lots 2,000 HK$ 42,500
5 lots 2,500 HK$ 53,125
6 lots 3,000 HK$ 63,750
7 lots 3,500 HK$ 74,375
8 lots 4,000 HK$ 85,000
9 lots 4,500 HK$ 95,625
10 lots 5,000 HK$ 106,250
12 lots 6,000 HK$ 127,500
14 lots 7,000 HK$ 148,750
16 lots 8,000 HK$ 170,000
18 lots 9,000 HK$ 191,250
20 lots 10,000 HK$ 212,500
24 lots 12,000 HK$ 255,000
28 lots 14,000 HK$ 297,500
32 lots 16,000 HK$ 340,000
40 lots 20,000 HK$ 425,000
50 lots 25,000 HK$ 531,250
60 lots 30,000 HK$ 637,500
100 lots 50,000 HK$ 1,062,500
200 lots 100,000 HK$ 2,125,000
300 lots 150,000 HK$ 3,187,500
400 lots 200,000 HK$ 4,250,000
Pool B
Lots SubscribedShares SubscribedSubscription Amount (HKD)
700 lots 350,000 HK$ 7,437,500

Stock Connect Inclusion Analysis

26Q4 Regular Review
Inclusion Pathway Regular Path
Avg Daily HK Mkt Cap HK$ 689.8M
Est. Threshold HK$ 9.71B
Analysis Result HK market cap below threshold, need +1308%

Valuation & Financials

Market Cap (at Offer Price)HK$ 5,183,661,250
H-Share Market Cap (at Offer Price)HK$ 1,309,129,965
Pre-IPO Valuation (Last Round)Not disclosed
P/E Ratio不适用(公司处于亏损状态)
Profit/Loss Status亏损人民币340.3百万元
Period-End Cash Balance人民币453.7百万元
Listing ExpensesTo be extracted
Listing Expenses / Funds RaisedTo be extracted
Total Pre-IPO InvestmentTo be extracted

Financial Data

Unit: '000 RMB
Income Statement
Item 2019
Other income and gains, net 1,855
Administrative expenses -3,230
Operating profit -586
Net finance costs -108
Profit before tax -10,694
Income tax expense 0
Profit for the year -10,694
Profit attributable to owners -10,694
Balance Sheet
Item 2019
Cash and cash equivalents 16,219
Total current assets 19,648
Total assets 27,606
Total current liabilities 5,545
Total liabilities 7,097
Total equity 20,509
Equity attributable to owners 20,509
Cash Flow Statement
Item 201920202021-06
Net cash from operating activities -860
Net cash from investing activities 217
Net cash from financing activities -1,046
Net increase in cash -949
Depreciation of PP&E 6,7957,5375,468
Depreciation of right-of-use assets 9051,1061,725
Purchase of PP&E -14,989-5,747-10,116
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
First Day CloseHK$ 20.1
First Day OpenHK$ 18.88
First Day Change-5.41%
First Day Volume3952000.0
First Day Turnover77091800.0
Use of Proceeds
1、62.0%,或273.9百萬港元用于撥付正在進行的確認性臨床試驗、注冊備案的籌備事宜以及我們的核心產品Bioheart?的計劃中商業化上市; 2、21.3%,或94.1百萬港元用于撥付在中國正在進行的隨機對照臨床試驗以及我們的腎神經阻斷在研產品第二代Iberis?的持續開發; 3、6.7%,或29.6百萬港元用于撥付我們管線中其他在研產品的研發、進行中臨床前研究及已規劃的臨床試驗; 4、10.0%,或44.2百萬港元作一般企業及營運資金用途。

Underwriting Syndicate

Sole Sponsor (1)
HUATAI FINANCIAL HOLDINGS (HONG KONG) LIMITED CE AOK809
Overall Coordinators (1)
HUATAI FINANCIAL HOLDINGS (HONG KONG) LIMITED CE AOK809
Joint Bookrunners (1)
HUATAI FINANCIAL HOLDINGS (HONG KONG) LIMITED CE AOK809
Joint Lead Managers (1)
HUATAI FINANCIAL HOLDINGS (HONG KONG) LIMITED CE AOK809

Cornerstone Investors

This stock has no cornerstone investors.

Directors & Management

PositionChinese nameEnglish Name
Chairman汪立—
Company Secretary王雲磬、郭兆瑩—
No director data available.

Major Shareholders

Major Shareholders & Holdings汪立透過Winning Powerful Limited、上海百哈特、上海百心安通等合共持有約43.75%股權
About this page

This page shows Bioheart-B (02185) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements. New to IPO subscription? See Hong Kong IPO Subscription 101.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect